ENZYMATICA AB Enzymatica AB mouth spray against the common cold will be launched in Turkey, following the approval as a medical device in the country. This opens a new market of more than 80 million consumers. Now Enzymatica's mouth spray against the common cold will be launched in Turkey, following the approval as a medical device by TITCK, the Turkish Medicines and Medical Devices Agency.
The product will be marketed, sold, and distributed in Turkey by Sanofi Consumer Health Care under one of its own brands.
